Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Jun 30.
Published in final edited form as: Cancer Prev Res (Phila). 2022 Jun 2;15(6):411. doi: 10.1158/1940-6207.CAPR-22-0204

Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1

Kotha Subbaramaiah, Louise R Howe, Xi Kathy Zhou, Peiying Yang, Clifford A Hudis, Levy Kopelovich, Andrew J Dannenberg
PMCID: PMC9245248  NIHMSID: NIHMS1818635  PMID: 35652223

This article (1) has been retracted at the request of the authors. There was evidence of data falsification or fabrication found in two figures. Suspicious duplications of band images were found in Fig. 2 and Fig. 4E. A copy of this Retraction Notice was sent to the last known e-mail addresses for the 7 authors. All authors agreed to the retraction. The authors apologize to the scientific community and deeply regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.

Reference

  • 1.Subbaramaiah K, Howe LR, Zhou XK, Yang P, Hudis CA, Kopelovich L, et al. Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1. Cancer Prev Res 2012;5:1183–94. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

RESOURCES